# Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

> **NCT00670228** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 34 (actual)

## Conditions studied

- AMI

## Interventions

- **DRUG:** Insulin Glargine (LANTUS)
- **DRUG:** Insulin Glulisine (Apidra)
- **DRUG:** Standard Therapy

## Key facts

- **NCT ID:** NCT00670228
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to Negative feasibility assessment of recruiting the planned number of subjects within the study timelines
- **Last updated:** 2011-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670228, "Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00670228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*